CANF · Can-Fite Biopharma Ltd American Depositary Shares each representing two (2)
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow CANF by emailGet an email when CANF pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CANF, unsubscribe in one click. Privacy
📣 What CANF Says Is Next
Q4 2026 · “Results are expected during Q4 2026/Q1 2027.”
Company press release, Jul 6, 2026 · SEC filing
Q4 2026 · “An interim analysis from the Phase III study is expected to be in approximately Q4 2026.”
Company press release, Dec 16, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full CANF picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CANF and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.